Euro-Med Laboratories Phil (EURO) Stock Overview
Manufactures and sells various pharmaceutical products in the Philippines and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
EURO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Euro-Med Laboratories Phil., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₱1.03 |
| 52 Week High | ₱1.10 |
| 52 Week Low | ₱0.72 |
| Beta | 0.15 |
| 1 Month Change | 1.98% |
| 3 Month Change | 8.42% |
| 1 Year Change | 17.05% |
| 3 Year Change | 17.05% |
| 5 Year Change | -62.13% |
| Change since IPO | 69.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| EURO | PH Pharmaceuticals | PH Market | |
|---|---|---|---|
| 7D | -1.0% | -0.5% | -2.3% |
| 1Y | 17.0% | 11.9% | -8.5% |
Return vs Industry: EURO exceeded the PH Pharmaceuticals industry which returned 11.9% over the past year.
Return vs Market: EURO exceeded the PH Market which returned -8.5% over the past year.
Price Volatility
| EURO volatility | |
|---|---|
| EURO Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PH Market | 11.5% |
| 10% least volatile stocks in PH Market | 2.7% |
Stable Share Price: EURO has not had significant price volatility in the past 3 months compared to the PH market.
Volatility Over Time: EURO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,718 | Georgiana Evidente | www.euromedlab.net |
Euro-Med Laboratories Phil., Inc. manufactures and sells various pharmaceutical products in the Philippines and internationally. It manufactures and distributes large and small volume parenterals that are used as solvents for other drugs; sterile water for injection; and other solutions for ophthalmic, inhalation, irrigation, and dialysis. The company also offers specialty fluids comprising dialysis solutions for the treatment of acute or chronic renal failure; hemodialysis solution, a concentrated solution of electrolytes in water for injection; irrigation solutions, which are sterile solutions that are used to bathe and flush open wounds or body cavities; mannitol injection, an osmotic diuretic, which promotes the excretion of water; Dextran 70, a fluid to expand blood volume; and Metronidazole for infections of gum and dental cavities, and pressure sores, as well as pelvic area, brain and lung, bones, gastrointestinal, genital tract, and blood infections.
Euro-Med Laboratories Phil., Inc. Fundamentals Summary
| EURO fundamental statistics | |
|---|---|
| Market cap | ₱4.28b |
| Earnings (TTM) | ₱393.83m |
| Revenue (TTM) | ₱6.71b |
Is EURO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EURO income statement (TTM) | |
|---|---|
| Revenue | ₱6.71b |
| Cost of Revenue | ₱4.45b |
| Gross Profit | ₱2.26b |
| Other Expenses | ₱1.87b |
| Earnings | ₱393.83m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.096 |
| Gross Margin | 33.69% |
| Net Profit Margin | 5.87% |
| Debt/Equity Ratio | 64.6% |
How did EURO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/05 16:21 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Euro-Med Laboratories Phil., Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.